Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes

European Journal of Gynaecological Oncology

Volumn 29, Issue 1, 2008, Pages 19-25

  Kalogiannidis, I ^a,d   Bobos, M ^a   Papanikolaou, A ^a   Makedos, A ^a   Amplianitis, I ^b   Vergote, I ^c   Nenopoulou, E ^a   Makedos, G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d NONE   (Greece)

Author keywords

Bcl 2; Endometrial adenocarcinoma; ER; p53; PR, TMA

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40449126356     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parker S.L., Tong T., Bolden S., Wingo P.A.: "Cancer statistics". CA Cancer J. Clin., 1966, 46, 5.
2. Gatta G., Lasota M.B., Verfecchia A. and the EUROCARE Working Group: "Survival of european women with gynaecological tumours during the period 1978-1989". Eur. J. Cancer, 1998, 34, 2218.
3. Trope C.G., Alektiar K.M., Sabbatini P.J., Zaino RJ.: "Corpus: epithelial tumors. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R.R., Markman M., Randall M.E. (eds.). Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott Williams and Williams, 2005, 835.
4. Taskin M., Lallas T.A., Barber H.R.K., Shevchuk M.M.: "Bcl-2 and p53 in endometrial adenocarcinoma". Mod. Pathol., 1997, 10, 728.
5. Yamauchi N., Sakamoto A., Uozaki H., Iihara K., Machinami R.: "Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptors and proliferative activity". Int. J. Gynecol. Pathol., 1996, 15, 202.
6. Lu Q.L., Abel P., Foster C.S., El-Nasir L.: "Bcl-2. Role in epithelial differentiation and oncogenesis". Hum. Pathol., 1996, 27, 102.
7. Tabibzadeh S., Zupi E., Babaknia A., Liu R., Marconi D., Romanini A.: "Site and menstrual cycle depended expression of proteins of the tumors necrosis factor (TNF)-receptors family, and bcl-2 oncoprotein and phase-specific production of the TNF alpha in the human endometrium". Hum. Reprod., 1995, 10, 277.
8. Otsuki Y., Misaki O., Sugimoto O., Ito Y., Tsujimoto Y., Akao Y.: "Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle". Lancet, 1994, 344, 28.
9. Gompel A., Sabourin J.C., Martin A., Yaneva H., Audouin J., Decroix Y., Poitout P.: "Bcl-2 expression in normal endometrium during menstrual cycle". Am J. Pathol., 1994, 144, 1195.
10. Chan W.K., Mole M.M., Levison D.A., Ball P.R.Y., Lu Y.L., Patel K., Handy A.M.: "Nuclear and cytoplasmatic bcl-2 expression in endometrial hyperplasia and adenocarcinoma". J. Pathol., 1995, 177, 241.
11. Miyashita T., Harigai M., Hanada M., Reed J.C.: "Identification of p53 dependent negative response element in the bcl-2 gene". Cancer Res., 1994, 54, 3131.
12. Wang Y., Szekely L., Okan J., Klein G., Wiman G., Wiman K.L.: "Wild type p53-triggered apoptosis is inhibited by bcl-2 in v-myc-induced T-cell lymphoma line". Oncogene, 1993, 8, 3427.
13. Lax S.F.: "Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification". Virchows Arch., 2004, 444, 213.
14. Geisler J.P., Geisler H.E., Wiemann M.C., Zhou Z., Miller G.A., Crabtree: "P53 expression as a prognostic indicator of 5-years survival in endometrial cancer". Gynecol. Oncol., 1999, 74, 468.
15. Ambros R.A., Vigna P.A., Figge J., Kallakury B.V., Mastrangelo A., Eastman A.Y. et al.: "Observation on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53". Cancer, 1994, 73, 1686.
16. Ferrandina G., Ranelleti F.O., Gallota V., Martinelli E., Zannoni G.F., Gessi M., Scambia G.: "Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER) and progesterone (PR), p53, ki67, and neu protein in endometrial cancer". Gynecol. Oncol., 2005, 98, 383.
17. Ohkouchi T., Sakuragi N., Watari H.: "Prognostic significance of bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma". Am. J. Obstet. Gynecol., 2002, 187, 353.
18. Announcements FIGO stages - 1988 revision. Gynecol. Oncol., 1989, 35, 125.
19. Ayhan A., Taskiran C., Yuce K., Kucukali T.: "The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma". Int. J. Gynecol. Pathol., 2002, 22, 71.
20. Papanikolaou A., Kalogiannidis I., Goutzioulis M., Misailidou D., Makedos A., Vergote I., Makedos G.: "Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer". Arch. Gynecol. Obstet., 2006, 274, 91.
21. Oreskovic S., Babic D., Kalafatic D., Barisic D., Beketic-Oreskovic L.: "A significance of immunohistochemical determination of steroid receptors, cell proliferation factor KI-67 and protein p53 in endometrial carcinoma". Gynecol. Oncol., 2004, 93, 34.
22. Carcangiu M.L., Chambers J.T., Voynick I.M., Pirro M., Schwartz P.E.: "Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations". Am. J. Clin. Pathol., 1990, 94, 247.
23. Kaplan E., Meyer P.: "Non parametric estimation from incomplete observations". J. Am. Stat. Assoc., 1958, 53, 457.
24. Pijnenborg J.M.A., van de Broek L., dam de Veen G.C.: "TP53 overexpression in recurrent endometrial carcinoma". Gynecol. Oncol., 2006, 100, 397.
25. Hamel N.W., Sebo T.J., Wilson T.O., Keeney G.L., Roche P.C., Suman V.J. et al.: "Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma". Gynecol. Oncol., 1996, 62, 192.
26. Knifeman T.H., Trgovac T.L., McGaughy V.R., Vaccarello L.: "Bcl-2 expression in endometrial hyperplasia and carcinoma". Gynecol. Oncol., 1996, 63, 318.
27. Lukes A.S., Kohler B.A., Pieper C.F., Kerns B.J., Bentley R., Rodriguez G.C. et al.: "Multivariable analysis of DNA ploidy p53, and Her-2/neu as prognostic factor in endometrial cancer". Cancer, 1994, 73, 2380.
28. Kounelis S., Kapranos N., Kouri E., Coppola D., Papadaki H., Jones M.W.: "Immunohistochemical profile of endometrial adenocarcinoma: A study of 61 cases and review of the literature". Mod. Pathol., 2000, 13, 379.
29. Zheng W., Cao P., Zheng M., Kramer E.E., Godwin T.A.: "p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary and endometrium subtypes". Gynecol. Oncol., 1996, 61, 167.
30. Soong R., Robbins P.D., Dix B.R., Grieu F., Lim B., Knowles S. et al.: "Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas". Hum. Pathol., 1996, 27, 1050.
31. Stewart R.L., Royds J.A., Burton J.L., Heatley M.K., Wells M.: "Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein". Histopathology, 1998, 33, 440.
32. Koul A., Bendahl P.-O., Borg A., Ferno M., Lidebring M.F., Hogberg T. et al.: "TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer". Int. J. Gynecol. Cancer, 2002, 12, 362.
33. Sakuragi N., Ohkouchi T., Hareyama H., Ikeda K., Watari H., Fujimoto T. et al.: "Bcl-2 expression and prognosis of patients with endometrial carcinoma". Int. J. Cancer, 1998, 79, 153.
34. Geisler J.P., Geisler H.E., Wiemann M.C., Zhou Z., Miller G.A., Crabtree W.: "Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma". Gynecol. Oncol., 1998, 71, 305.
35. Chhieng D.C., Ross J.S., Ambros R.A.: "Bcl-2 expression and the development of endometrial carcinoma". Mod. Pathol., 1996, 9, 701.
36. Nanbu K., Konishi J., Komatsu T., Mandai M., Yamamoto R., Kuroda H. et al.: "Expression of heat shock protein HSP70 and HSP90 in endometrial carcinomas: correlation with clinicopathology, sex steroid receptors status and p53 protein expression". Cancer, 1996, 77, 330.
37. Erdem O., Erdem M., Dursum A., Akyol G., Erdem A.: "Angiogenesis, p53 and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables". Int. J. Gynecol. Path., 2003, 22, 254.
38. Pisani A.L., Barbuto D.A., Chen D., Ramos L., Lagasse L.D., Karlan B.Y.: "Her-2/new, p53 and DNA analysis as prognostic for survival in endometrial carcinoma". Obstet. Gynecol., 1995, 85, 729.
39. Ito K., Watanabe K., Nasim S., Sasano H., Sato S., Yajima A. et al.: "Prognostic significance of p53 overexpression in endometrial cancer". Cancer Res., 1994, 54, 4667.
40. Kohler M.F., Berchuck A., Davidoff A.M., Humphery P.A., Dodge R.K., Iglehart J.D. et al.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Res., 1992, 1622.
41. Straughn J.M. Jr, Huh W.K., Orr J.W. Jr, Kelly F.J., Roland P.Y., Gold M.A. et al.: "Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy". Gynecol. Oncol., 2003, 89, 295.
42. Mohan D.S., Samuels M.A., Selim M.A., Shaladi A.D., Ellis R.J., Samuels J.R., Yun H.J.: "Long-term outcomes of therapeutic pelvic lymphadenectomy for Stage I endometrial adenocarcinoma". Gynecol. Oncol., 1998, 70, 165.